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            Amendments from Version 1
The differences of the second version of "Statistical analysis plan 
for the WOMAN-ETAPlaT study: Effect of tranexamic acid on 
platelet function and thrombin generation" has been based on the 
comments from referees:
1. Removed the exploratory subgroup analysis section, because 
the total sample size was small and the subgroup analyses run 
the risk of false positive. Also, it was removed a section with 
evidence about effect of TXA on thrombin generation, because 
some evidence it was provided at the protocol paper of ETAPlaT 
sub-study.
2. We added a flowchart according to CONSORT to report 
the participant progress in the ETAPlaT sub-study (Figure 1), 
allocation of patients in TXA or placebo group, lost of follow up 
and exclusion from analysis. Two sections were added, one 
section for safety report for all patients randomized in the sub-
study, about adverse events and serious adverse events. Another 
section added was about adherence, to report measures of 




ADPtest: Test of Adenosine Di Phosphate (ADP); AUC: Area Under 
Curve; CI: confidence Interval; CONSORT: Consolidated Standards 
of Reporting Trials; ETP: Endogenous Thrombin Potential; FAS: 
Full Analysis Set; FV: Coagulation Factor V; FVIII: Coagulation 
Factor VIII; CBC: Complete Blood Count; IBE: Institute for 
Medical Information Sciences, Biometry and Epidemiology; Hb: 
Hemoglobin; Ht: Hematocrit; LT: Lag Time; PtH: Peak to Height; 
MPV: Mean Platelet Volume Mean Platelet Volume; PP: Per-
Protocol; R: software package R (r-project.org); SAP: Statistical 
Analysis Plan; SD: Standard Deviations; SOP: Standard Operating 
Procedure; TGA: Thrombin Generation Assay; TXA: Tranexamic 
Acid; TRAPtest: Test of Thrombin Receptor of Thrombocyte; 
vWF: Coagulation Factor Von Willebrand.
Preface
The purpose of the statistical analysis plan (SAP) is to ensure the 
credibility of the study findings by pre-specifying the statistical 
approaches to the analysis of the study data prior to hard locking 
the database and unblinding of the WOMAN ETAPlaT trial data. 
To prevent outcome bias and selective reporting, a detailed SAP is 
presented in order to avoid post hoc decisions that may influence 
the interpretation of the results and the statistical analyses of the 
final data.
This SAP is a technical extension of the WOMAN ETAPlaT study 
protocol (Version 1.1, dated August 29, 2014), which is published 
elsewhere (Dallaku et al., 2016). The SAP follows the principles of 
the International Conference on Harmonization (ICH) guidelines 
E3, E6 and E9 (ICH, 2016).
Study objectives and endpoints of WOMAN-ETAPlaT
Objectives of the study
Primary objectives: This study will assess if TXA, by inhibiting 
the plasmin, has an effect on decrease over time on the continuous 
response variable, thrombin generation assay (TGA) parameter: 
endogenous thrombin potential (ETP). Secondary objectives: 
evaluation of the effect of TXA on women with PPH, through 
monitoring the platelet function (multiplate analyser), plas-
matic levels of fibrinogen, D-dimer, coagulation factor V (FV), 
coagulation factor VIII (FVIII), coagulation factor von Willebrandt 
(vWF) and other TGA parameters: lag time (LT), time to peak 
(TtP), and peak height (Ph).
Endpoints
Primary efficacy endpoint. The primary efficacy endpoint is 
the TGA parameter – ETP (nM/minute). Values of ETP will be 
measured in venous blood samples. Blood samples will be col-
lected at the baseline and at 30 ±15 minutes after the first dose of 
study treatment is given. Analysis will be performed on processed, 
separated platelet poor plasma, and preserved in deep freeze, as 
described in the ETAPlaT protocol (Dallaku et al., 2016).
Secondary efficacy endpoints. Secondary outcomes will include 
parameters measuring the effect of TXA on other TGA parameters 
(LT, TtP, and Ph - we will transform variables prior to analy-
sis if there is evidence that distributions are skewed), fibrinogen, 
D-dimer and coagulation factors V, VIII, vWF (measured on 
processed plasma samples as described on primary endpoint) 
and platelet function analysed by Multiplate® tests (ADPTest, 
TRAPTest – measured on whole blood). 
Study methods
Study design
The WOMAN-ETAPlaT is a sub-study of the WOMAN trial, 
an international randomised, double blinded, placebo-controlled 
trial. The ETAPlaT sub-study has the same study design as the 
WOMAN trial, but includes some additional laboratory tests. 
Women who fulfil the eligibility criteria for the WOMAN trial, 
including adult women clinically diagnosed with primary PPH 
after a vaginal delivery (>500 ml blood loss), a caesarean delivery 
(>1000 mL blood loss), or enough blood loss to compromise the 
haemodynamic status will be randomized. Women with PPH for 
whom the physician believes there is an indication or contraindica-
tion to use TXA, will be excluded.
Immediately after randomization, women will receive the trial 
treatment by i/v administration of either TXA (1 gram) or placebo 
(NaCl solution 0.9%). If after 30 minutes the haemorrhage contin-
ues or if it stops and restarts within 24 hours after randomization, a 
second dose may be given. This second dose is not relevant for the 
current sub-study.
Randomisation, blinding and ethics approval
Packs with study drugs were prepared according to the randomi-
zation list, generated by an independent statistician. The active 
study drug (TXA) and placebo (NaCl 0.9%) will be identical in 
appearance, and randomization number will be used for identifica-
tion of packs. Each box has eight packs of study drugs, and the 
lowest number pack will be used first. After completing the con-
sent procedure, eligible patients are randomized to receive either 
TXA or placebo. Both the patients and the medical representatives 
participating in the study are masked to the treatment distribu-
tion. Ethical approval was obtained in July 11, 2013 by National 
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Ethics Committee in Tirana, Albania (ref. 62 and 81) and in 
October 28, 2013 by London School of Hygiene and Tropical 
Medicine, UK (ref. 6518).
Study variables and study schema
Details concerning the baseline (treatment) and follow-up (post 
treatment) period together with the frequency and timing of 
relevant variables or assessments are displayed at Table 1.
Sample size
The sample size calculation is focused on the first component of 
the primary endpoint: change over time of ETP in women with 
PPH. In a previous study (McLean et al., 2012) ETP in patients 
with term pregnancy, within each subject group, was normally 
distributed with a mean of 2410 nM/min and standard deviation 
(SD) of 543 nM/min.
Assuming a correlation of 0.6 between two time points, the 
standard deviation of the change can be calculated as 485 
{sqrt[2×543^2×(1-0.6)])}. We assume a decrease in ETP of 10% 
(243 nM/min) over time in the TXA group and no change in the 
placebo group. To detect an ETP difference of 243 nM/min between 
groups at a 5% significance level with a power of 80%, two 
groups each with 88 patients are needed.
A correlation of 0.6 is seen as a conservative estimate as the within 
individual changes in TGA over time is strictly controlled, which 
implies a high correlation between time points.
General considerations
Timing of analyses
Participant recruitment started on 4 November 2013 and was com-
pleted on 13 January 2015. The final participant follow-up was 
completed on 04 March 2015.
All final analyses will be performed on the database at LSHTM 
(London, UK) which consists of several tables (Table 1). After 
documenting all data collection forms (DCF) data, data cleaning 
and query resolution, the following prerequisites for unblinding 
must be fulfilled: the resolution of all queries concerning DCF and 
laboratory results, and the finalisation of the SAP document.
All these processes before database locking must take place to 
comply with requirements.
Following data integrity checks the database will be locked after 
October 2016 and the statistical analysis specified in the SAP 
and approved by the Trial Steering Committee (TSC), will be 
performed in advance of the WOMAN trial database lock. In the 
event the TSC approves analysis before the end of the WOMAN 
trial, only the independent Data Monitoring Committee (DMC) 
statistician will be aware of each participant’s treatment 
allocation. Each participant will be allocated a unique identifier 
(different from that of the WOMAN trial before unblinding). This 
is to ensure that the WOMAN trial blinding is not compromised in 
any way.
Analysis populations
Full analysis set (FAS). The primary efficacy analysis follows the 
principle of intention to treat (ITT), which implies that study data 
are analysed based on the original allocation of patients, regardless 
of a treatment received. Withdrawals, participants lost to follow-up 
and participants who did not adhere fully to the WOMAN ETAPlaT 
study protocol, will not be excluded from the primary efficacy anal-
yses provided that they satisfy major entry criteria. Women who 
have withdrawn consent to use their data will be excluded from 
the ITT analysis. Women with a follow-up measure but no baseline 
measure will be included in the ITT analysis (Figure 1).
Per-protocol set (PP). The PP set consists of all patients who did 
not substantially deviate from the WOMAN ETAPlaT protocol 
as to be determined on a per-subject basis. The PP set of subjects 
defining a subset of the FAS is characterised as follows: (1) with 
measurements of outcome available, (2) no major protocol viola-
tions are detected: (a) Failure to administer the study drug (first 
dose), (b) Failure to collect blood sample (baseline or follow-up), 
(c) Exceeding time-frame of 30 min ± 15 minutes between the 
study drug administration and follow-up blood sample collection.
Covariates and subgroups
There exists no a priori hypothesis of subgroup differences 
regarding treatment effects. Hence, no pre-planned confirmatory 
subgroup analyses will be performed to explore evidence for a dif-
ference in treatment effects (interaction effect).
Summary of study data
All continuous variables will be summarised by treatment group 
(TXA/placebo) using the following descriptive statistics: sample 
size (N), mean ±standard deviation (SD), median, maximum and 
minimum. The absolute frequency and percentages of observed levels 
will be reported for all categorical variables. Summary statistics 
will be displayed overall and stratified by the treatment group. The 
key baseline characteristics selected are presented in Table 2.
Baseline characteristics
In a study about the mode of anaesthesia related to PPH after 
caesarean deliveries, a significantly higher amount of blood loss 





– ADPtest (.csv file)
Baseline data and 30 ± 15 min 
after study treatment
MultiplateAnalyser test 
– TRAPtest (.csv file)
Baseline data and 30 ± 15 min 
after study treatment
Thrombin generation assay 
(.csv file)
Baseline data and 30 ± 15 min 
after study treatment
Coagulation factors vW, V, 
VIII, Fib, and DDim (.csv file)
Baseline data and 30 ± 15 min 
after study treatment
Clinical data collection forms 
(.csv file) Baseline data and follow-up
Full blood count (.csv file) Baseline data and within 12 hrs after randomization
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Figure 1. ETAPlaT sub-study flowchart:* Patients for whom there is no information on the primary endpoint.
previously reported (Aksoy et al., 2015). The reduction of blood 
loss in neuroaxial anaesthesia maybe was caused partly from hypo-
tension and by fluids infused in these women (Heesen et al., 2013). 
Another role in increased blood loss during general anaesthesia 
was reported from volatile anaesthetics which may decrease the 
myometrium contractility (Yoo et al., 2006) and as result can cause 
uterine atony. Also, volatile anaesthetics with their inhibition effect 
on platelet aggregation (Yuki et al., 2013) can increase the risk for 
PPH.
Dionne et al. (2015) mentioned that prolonged second stage 
labour was associated with increased risk and severity of PPH. 
Other potential risk factors for PPH were null-parity, high birth-
weight and antepartum anaemia, where low levels of haemoglobin 
before delivery were associated with a low efficacy of haemostasis 
mechanism promoted by red cells and platelets (Biguzzi et al., 
2012), and as result with an increased risk for PPH.
Efficacy analyses of primary outcome
Both groups of randomised patients, those allocated to the TXA 
group and placebo group will be compared and analysed on an 
intention-to-treat basis, irrespective of treatment given. The results 
will be presented as appropriate effect estimates with a measure 
of precision (95% CI). In analysis of the primary outcome(TGA– 
ETP), the TXA group will be compared with the placebo group, 
based on analysis of covariance (ANCOVA) which adjusts for the 
baseline measurement of the respective outcome. In a sensitivity 
analysis we also add an adjustment for the length of time between 
two measurements (30±15 minutes) of the baseline and follow-up 







Patient height, weight, BMI
Parity: nullipara (0), multipara (>1)
Gestational age at birth: <37 or ≥37 weeks
Any concomitant diseases of pregnancy:
 Preclampsia, Chorioamnionitis, Diabetes, 
Placental abruption, Placenta previa, Previous 
PPH
Use of anaesthesia: 
General or spinal or none
Duration of labour of vaginal births (min) 
1st, 2nd and 3rd stage of labour 
Fetal birth weight: 
< 4000 gr or ≥ 4000 gr
Hb level at entry of the study
Platelet count at entry of the study
Fibrinogen level at entry of the study
Amount of blood loss
Primary cause of PPH 
Atony, placenta, trauma, other
Mode of delivery:vaginal- caesarean
Additional doses of uterotonics
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Efficacy analyses of secondary outcomes
The same analyses as for primary outcome will be performed for 
the blood parameters which are secondary endpoint parameters of 
Multiplate© tests (ADPtest and TRAPtest), fibrinogen, D-dimer, 
coagulation factors V, VIII, vWF and other TGA parameters 
(lag time, time to peak, peak height) (Table 4). The results will 
be presented as appropriate effect estimates with a measure of 
precision (95% CI).
All statistical analyses will be conducted with the statistics 
package R and STATA.
Influence of pregnancy diseases and PPH causes on the 
TXA effect for study outcomes
In pregnant women diagnosed with preeclampsia, preterm 
labour and chorioamnionitis, was found an increased thrombin 
generation (Mastrolia et al., 2014). Chaiworapongsa et al. (2002) 
also reported increased thrombin generation in patients diagnosed 
with preeclampsia and fetal growth restriction. Macey et al. (2010) 
comparing normal pregnancies with and without preeclampsia, 
reported an increased thrombin formation and increased platelet 
activation. Increased thrombin generation and platelet activity was 
found also in women with a history of preeclampsia (Rafik Hamad 
et al., 2009).
There is evidence that the haemostatic impairment that occurs 
in haemorrhage during pregnancy and delivery is different from 
trauma-induced haemorrhage. The type and rate of onset of 
coagulopathies differ depending on the main cause of obstetric 
haemorrhage (Collis & Collins, 2015). Regarding haemostasis 
changes during obstetric haemorrhage, there is little data. The 
type, severity and rate of onset of the coagulopathy vary with the 
aetiology of bleeding.
Allard et al. (2014) raised the question, whether women with post-
partum haemorrhage exhibit different changes from other patients 
who have haemorrhage during general surgery or trauma? Some 
of the underlying causes of postpartum haemorrhage such as uter-
ine atony and genital tract trauma were often associated with no 
significant coagulopathy (Collins et al., 2014). But, when the cause 
of PPH was placental abruption, it may be associated with rapid 
consumptive coagulopathy characterised with clinically severe 
haemostatic impairment (Thachil & Toh, 2009).
Influence of PPH severity, fibrinogen and platelet count on 
the TXA effect for study outcomes
Low plasmatic level of fibrinogen such as 2 – 3 g/L and especially 
less than 2 g/L at the beginning or on-going of PPH, was associ-
ated with an increased amount of blood loss, increased need for 
Table 4. Effect of tranexamic acid on coagulation factors and platelet function.
TXA (n) Placebo (n) Difference 95% CIP-value








FV               (%)
FVIII            (%)







Primary outcome Before After* Delta Before After* Delta
TGA – ETP (nM*min)
* 30 minutes
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blood transfusion and requirements for invasive procedures. Low 
platelet number at the diagnosis of PPH was associated with the 
requirement for invasive procedures (Collins et al., 2014). Simon 
et al. (1997), observed an increased frequency of PPH, when in 
early labour platelet count is <100000/mm³ or fibrinogen level is 
<2.9mg/L or both. A study has reported that thrombocytopenia 
<80 000/mm³ was associated with an increased incidence of 
severe PPH (Dikman et al., 2014), however, another study did not 
found any association between thrombocytopenia and severe PPH 
(Jones et al., 2016).
A systematic review (Simonazzi et al., 2016) confirmed that TXA 
can significantly decrease the incidence of PPH with an amount 
of blood loss >500 ml and severe PPH with blood loss > 1000ml. 
Consume of coagulation factors and platelets were reported in cases 
with severe postpartum bleeding. The decrease of fibrinogen level, 
antithrombin activity, and the platelet count was observed in PPH 
cases with blood loss >2000 ml.
A series of graphs will present each TGA parameter (ETP, LT, TtP, 
Ph) as a panel of 4 boxplots which show the measured values for 
the treatment groups split with respect to baseline platelet count 
categorized as follows: <50000, 50000–100000, 100000–150000, 
≥ 150000 (Figure 2). Similar graphs will display the coagulation 
factors (FV, FVIII, vWF, fibrinogen and D-dimer) and Multipla-
tetests (ADPtest and TRAPtest) measured values, with respect 
to platelet count for both treatment groups. Differences between 
the TXA/placebo groups will be tested using the non-parametric 
Kruskall-Wallis test.
Definition of boxplots: The publication will use the boxplot as 
implemented in the basic statistics package of R by the function 
“boxplot.stats”. The two ‘hinges’ are versions of the first and third 
quartile. They equal the quartiles for odd n (where n <- length(x)) 
and differ for even n. The notches extend to +/-1.58 IQR/sqrt(n). 
See in Chambers et al. (1983, p. 62), given in McGill et al. 
(1978, p. 16).
Baseline fibrinogen level and a panel of 7 dot-plots showing the 
corresponding individual measurements for each individual 
patient with respect to TGA-ETP, FV, FVIII, vWF, D-dimer, 
ADPtest and TRAPtest for both treatment groups TXA/placebo 
(Figure 3).
The dots will be color-coded with respect to the treatment groups, 
a smoother will be presented in the corresponding colour, the 
Spearman correlation will be calculated and a 95% CI for each 
treatment group will be presented. Also, the difference between the 
correlation coefficients of the treatment groups will be calculated 
and a 95% confidence interval will be presented. The confidence 
intervals related to the Spearman correlation coefficient will be 
calculated by bootstraping.
Two panels of graphs will present the ADPtest parameters as 
well as the TRAPtest parameters. They will show individual 
measurements for aggregation, velocity, and AUC of TXA/ 
placebo groups correlated with individual platelet count. These 
graphs (similar to Figure 2) will be produced for baseline, after 
treatment and change values.
Per-protocol analyses
All analyses as described in of the section ‘Efficacy analysis for 
primary and secondary outcomes’ will be repeated using the PP 
analysis set.
Figure 2. Effect of TXA on TGA parameters, regarding the platelet count before randomization (graph model using arbitrary data). 
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Safety
For all patients randomized in the ETAPlaT study who received 
TXA or placebo, from the moment of randomization and until 42 
days later, any treatment safety data is available. Adverse events 
(AE) and serious adverse events (SAE), classified on the basis of 
MedDRA terminology (ICH, 2016), will be reported to an inde-
pendent data monitoring committee (DMC), which is already in 
place for the WOMAN trial. All information regarding the AEs, 
SAEs will be registered for each patient affected, by date of onset 
and resolution, severity, frequency and outcome of AEs. The sta-
tistics will be organized by comparing TXA/placebo groups of 
patients with at least one adverse event. 
Adherence 
We report measures of compliance by trial arm: number of 
damaged or misallocated packs, time from randomisation to drug 
administration, time from baseline to 2nd measurement, number 
of 2nd doses administered.
Conclusions
This article presents the principles of statistical analysis of the 
WOMAN ETAPlaT study, in order to ensure the credibility of the 
study findings by pre-specifying the statistical approaches to the 
analysis of the study data. The detailed SAP presented will help 
to prevent outcome bias, selective reporting and to avoid post hoc 
decisions that may influence the interpretation of the results and the 
statistical analyses of the final data. The data from this study will 
provide evidence for the effect of TXA on thrombin generation, 
platelet function and coagulation factors in women with PPH.
Author contributions
KD, UM, HS, IR, PE, SH, DB and MD have contributed to the 
drafting of the statistical analysis plan and have reviewed it critically. 
All authors approved the final version of the statistical analysis 
plan.
Competing interests
No competing interests were disclosed.
Grant information
This work was supported by the Wellcome Trust [094947]; London 
School of Hygiene & Tropical Medicine; Erasmus Mundus program 
ERAWEB [D2.12.048]; and Rudolf Marx Foundation. 
The funders had no role in study design, data collection and analysis, 
decision to publish, or preparation of the manuscript.
Figure 3. Effect of TXA on coagulation  factors and platelet  function,  regarding  the baseline fibrinogen  level  (graph model using 
arbitrary data).
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Comments from Louise Linsell




Page 4 Full analysis dataset, 1st paragraph
Please clarify that women who have withdrawn consent to use their data will be excluded from the ITT
analysis. Will women with a follow-up measure but no baseline measure be included in the ITT analysis?
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 Page 4 Per protocol set, 1st paragraph
The bullet points after "No major protocol violations were detected" are not clear and do not make sense.
In addition to completion of blood samples add "with measurements of outcome available"
Page 4 Covariates and subgroups
Please clarify all pre-specified subgroup analysis and methods of analysis, e.g. test for interaction and tie
up with paragraph on   and the  .Page 6 Exploratory subgroup analyses last paragraph on page 7
Provide detail on the coding of the sub group variables, and which outcomes will be included for which
subgroup variables all in one place. Will subgroup analysis be conducted on the ITT set, PP set or both?
Page 4 Summary of study data, 1st paragraph
Remove sentence, "If considered appropriate these data are summarised by centre as well." as there is
only one centre.
Page 5 Efficacy analyses of primary outcome
The last sentence refers to a subgroup analysis - this should go in the section detailing subgroup
analyses.
Page 5 Effect of TXA on thrombin generation, 1st and 2nd paragraph
Not sure why this text is included in the SAP at this point - it belongs either in the protocol or the
background.
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as a covariate  . The section headed   states:Efficacy analyses of primary outcome
In analysis of the primary outcome(TGA– ETP), the TXA group will be compared with the placebo group,
based on analysis of covariance (ANCOVA) which adjusts for the length of time between two
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